Biogen Inc. (BIIB) stock prices updated...
 

Biogen Inc. stock price, BIIB

Biogen Inc. stock chart:



Biogen Inc. close price: 286.9

Stock price forecast:

UP TO +3.39%
Target: 296.63

Total forecasts: 90
Reached: 48 (53.33%)

Total Win: 312.28 (113.30%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90914953.85%322.191.28%12,142.38-92.58-0.76%229.610.88%
30312477.42%214.012.55%2,023.67-15.37-0.76%198.642.31%
1415853.33%128.163.15%2,023.67-15.37-0.76%112.792.69%
78112.50%13.160.59%2,023.67-15.37-0.76%-2.21-0.10%

Showing 1-10 of 395 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-02-21288.94297.810000-00-00
2017-02-20288.94303.750000-00-00
2017-02-19288.94304.150000-00-00
2017-02-18288.94304.450000-00-00
2017-02-17290.13305.380000-00-00
2017-02-16292.64306.310000-00-00
2017-02-15285.14297.660000-00-00
2017-02-14278.91292.072017-02-15
2017-02-13274.76289.12017-02-15
2017-02-12274.76289.142017-02-15

Biogen Inc. latest news:


  • 12/20/2016 16:20:25

    Investors see Biogen CEO choice as friendly to potential takeover

    NEW YORK (Reuters) - The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.

  • 12/20/2016 14:18:51

    BRIEF-Biogen's board approves separation of Bioverativ

    * Biogen - for every 2 shares of co's common stock held of record on Jan 17 2017, shareholders will receive one share of Bioverativ common stock

  • 12/19/2016 14:30:49

    Biogen shares slip following announcement of new CEO

    Biogen Inc. shares slipped in the extended session Monday following a report, later confirmed by Biogen, that the biotech company will appoint a new chief executive. Biogen shares declined 0.6% to $277 after hours. Biogen said Chief Commercial Officer Michel Vounatsos will become CEO on Jan. 6, succeeding George Scangos, who has been CEO since 2010. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/19/2016 14:18:05

    Biogen shares slip on report of new CEO

    Biogen Inc. shares slipped in the extended session Monday following a report that the biotech company is set to appoint a new chief executive. Biogen shares declined 1.2% to $275.50 after hours. Biogen is planning on announcing Chief Commercial Officer Michel Vounatsos as its new CEO to succeed George Scangos as early as this week, according to Reuters, citing people close to the matter.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/08/2016 14:06:55

    Biogen shares rise 1.6% on leaked Alzheimer's drug data

    iogen Inc. shares rose 1.6% in afternoon trade after data from its Alzheimer's drug was leaked. Biogen has been the particular target of investor interest after the recent high-profile failure of Eli Lilly's Alzheimer's drug. Biogen shares have dropped 5.5% year-to-date, compared with a 9.9% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/25/2016 05:09:50

    What Eli Lilly's hard fall in Alzheimer's treatment race means for its competitors

    Late-stage Alzehimer's drug failure could hurt Biogen, Merck. Eli Lilly and Company (LLY) shares plunged 11% Wednesday to a two-year low, after the company's treatment for people with mild dementia due to Alzheimer's disease failed to meet the primary endpoint in a late-stage clinical trial. The failure, which several Wall Street analysts said was disappointing, could have negative implications for Eli Lilly's Alzheimer's portfolio and competitors including Biogen Inc. and...

  • More trends:

    Biolase, Inc.BIOL | BioLife Solutions, Inc.BLFS | BioLineRx Ltd.BLRX | BioMarin Pharmaceutical Inc.BMRN | BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP |